Karl Bélanger

机构：Centre Hospitalier de l’Université de Montréal

发表论文 61 篇 · 总被引 34087 次 · h-index 23

代表论文

• Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial (2023 · Nature Medicine · 被引 500)
• Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors (2019 · OncoImmunology · 被引 214)
• Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial (2026 · Nature Medicine · 被引 70)
• Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma (2017 · Journal for ImmunoTherapy of Cancer · 被引 56)
• Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial (2025 · Journal for ImmunoTherapy of Cancer · 被引 33)
• Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors (2022 · OncoImmunology · 被引 31)